

# Wioleta M Zelek

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3463375/publications.pdf>

Version: 2024-02-01

20  
papers

453  
citations

759233

12  
h-index

752698

20  
g-index

22  
all docs

22  
docs citations

22  
times ranked

831  
citing authors

#	ARTICLE	IF	CITATIONS
1	Development, Characterization, and in vivo Validation of a Humanized C6 Monoclonal Antibody that Inhibits the Membrane Attack Complex. <i>Journal of Innate Immunity</i> , 2023, 15, 16-36.	3.8	2
2	Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid organ cancers. <i>Immunology</i> , 2022, 165, 250-259.	4.4	21
3	Targeting complement in neurodegeneration: challenges, risks, and strategies. <i>Trends in Pharmacological Sciences</i> , 2022, 43, 615-628.	8.7	15
4	C5b-9 Membrane Attack Complex Formation and Extracellular Vesicle Shedding in Barrett's Esophagus and Esophageal Adenocarcinoma. <i>Frontiers in Immunology</i> , 2022, 13, 842023.	4.8	4
5	Terminal complement pathway activation drives synaptic loss in Alzheimer's disease models. <i>Acta Neuropathologica Communications</i> , 2022, 10, .	5.2	19
6	Development of a high-throughput SARS-CoV-2 antibody testing pathway using dried blood spot specimens. <i>Annals of Clinical Biochemistry</i> , 2021, 58, 123-131.	1.6	31
7	Measuring Total Classical Pathway and Activities of Individual Components of the Mouse Complement Pathway. <i>Bio-protocol</i> , 2021, 11, e4175.	0.4	3
8	Temporal development and neutralising potential of antibodies against SARS-CoV-2 in hospitalised COVID-19 patients: An observational cohort study. <i>PLoS ONE</i> , 2021, 16, e0245382.	2.5	14
9	The immune landscape of SARS-CoV-2-associated Multisystem Inflammatory Syndrome in Children (MIS-C) from acute disease to recovery. <i>IScience</i> , 2021, 24, 103215.	4.1	35
10	Cerebrospinal fluid complement system biomarkers in demyelinating disease. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1929-1937.	3.0	22
11	Monoclonal Antibodies Capable of Inhibiting Complement Downstream of C5 in Multiple Species. <i>Frontiers in Immunology</i> , 2020, 11, 612402.	4.8	16
12	Characterizing the original anti-C5 function-blocking antibody, BB5.1, for species specificity, mode of action and interactions with C5. <i>Immunology</i> , 2020, 161, 103-113.	4.4	11
13	Compendium of current complement therapeutics. <i>Molecular Immunology</i> , 2019, 114, 341-352.	2.2	110
14	Development and characterization of novel anti-C5 monoclonal antibodies capable of inhibiting complement in multiple species. <i>Immunology</i> , 2019, 157, 283-295.	4.4	20
15	Measurement of soluble CD59 in CSF in demyelinating disease: Evidence for an intrathecal source of soluble CD59. <i>Multiple Sclerosis Journal</i> , 2019, 25, 523-531.	3.0	9
16	Complement system biomarkers in first episode psychosis. <i>Schizophrenia Research</i> , 2019, 204, 16-22.	2.0	53
17	Absence of CD59 in Guinea Pigs: Analysis of the <i>Cavia porcellus</i> Genome Suggests the Evolution of a CD59 Pseudogene. <i>Journal of Immunology</i> , 2018, 200, 327-335.	0.8	4
18	Extracting the barbs from complement assays: Identification and optimisation of a safe substitute for traditional buffers. <i>Immunobiology</i> , 2018, 223, 744-749.	1.9	15

#	ARTICLE	IF	CITATIONS
19	Complement system biomarkers in epilepsy. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2018, 60, 1-7.	2.0	32
20	Characterizing a pH-switch anti-C5 antibody as a tool for human and mouse complement C5 purification and cross-species inhibition of classical and reactive lysis. <i>Immunology</i> , 2018, 155, 396-403.	4.4	14